REGULAR CONTENT
Final ID
501
Type
Original Scientific Research-Oral or Pos
Authors
A Saltarelli1, G Pelle2, E Notarianni3, V Pasqualini4, R Cianni5
Institutions
1S.M. GORETTI HOSPITAL, Latina, ITALY, 2S.M. Goretti Hospital, LATINA, ITALY, 3S.M.GORETTI HOSPITAL, LATINA, ITALY, 4S.M.GORETTI HOSPITAL, latina, italy, 5S.M. GORETTI HOSPITAL, ROMA, ITALY
Purpose
Yttrium-90 (Y90) radioembolization is a well-established treatment option for patients with unresectable liver tumors. Coil embolization of extrahepatic vessels is usually mandatory to avoid extrahepatic nontargeted implantation of Y90 microspheres.To test the Occlusafe microcatheter (Terumo, Japan) as new balloon antireflux microcatheter (2.7-2.8 F) for Y90 microspheres infusion.
Materials & Methods
9 patients with unresectable liver metastasis (6 colorectalcancer [CRC], 3 breast cancer [BC]) underwent to Y90 radioembolization. In all cases the Occlusafe catheter was used for microsphere infusion. Embolization of gastro-duodenal artery was not performed in all patients. In all cases Infusion was started after Dyna CT scan. The liver distribution of microspheres wasassessed by Y90 PET/CT the same day of the procedure.
Results
The procedure was performed in all patients without any complications. TheOcclusafe microcatheter allowed catheterization of the hepatic arteries even in difficult anatomical variants. Y90 PET/CT confirmed the intrahepatic distribution of the microsphereswithout extrahepatic nontargeted implantation in the gastro-duodenal territories.
Conclusions
The Occlusafe catheter is a valuable device to prevent reflux of Y90 microspheres during radioembolization. The system may expand the indicationsof radioembolization in those patients previously deemed unfit due to the high risk of extrahepatic microspheres implantation.
Final ID
501
Type
Original Scientific Research-Oral or Pos
Authors
A Saltarelli1, G Pelle2, E Notarianni3, V Pasqualini4, R Cianni5
Institutions
1S.M. GORETTI HOSPITAL, Latina, ITALY, 2S.M. Goretti Hospital, LATINA, ITALY, 3S.M.GORETTI HOSPITAL, LATINA, ITALY, 4S.M.GORETTI HOSPITAL, latina, italy, 5S.M. GORETTI HOSPITAL, ROMA, ITALY
Purpose
Yttrium-90 (Y90) radioembolization is a well-established treatment option for patients with unresectable liver tumors. Coil embolization of extrahepatic vessels is usually mandatory to avoid extrahepatic nontargeted implantation of Y90 microspheres.To test the Occlusafe microcatheter (Terumo, Japan) as new balloon antireflux microcatheter (2.7-2.8 F) for Y90 microspheres infusion.
Materials & Methods
9 patients with unresectable liver metastasis (6 colorectalcancer [CRC], 3 breast cancer [BC]) underwent to Y90 radioembolization. In all cases the Occlusafe catheter was used for microsphere infusion. Embolization of gastro-duodenal artery was not performed in all patients. In all cases Infusion was started after Dyna CT scan. The liver distribution of microspheres wasassessed by Y90 PET/CT the same day of the procedure.
Results
The procedure was performed in all patients without any complications. TheOcclusafe microcatheter allowed catheterization of the hepatic arteries even in difficult anatomical variants. Y90 PET/CT confirmed the intrahepatic distribution of the microsphereswithout extrahepatic nontargeted implantation in the gastro-duodenal territories.
Conclusions
The Occlusafe catheter is a valuable device to prevent reflux of Y90 microspheres during radioembolization. The system may expand the indicationsof radioembolization in those patients previously deemed unfit due to the high risk of extrahepatic microspheres implantation.